AbbVie Halts Brain Tumor Late-Stage Study
AbbVie halted the Phase III INTELLANCE-1 trial of depatuxizumab mafodotin in patients with newly diagnosed glioblastoma whose tumors have epidermal growth factor receptor amplification.
Lilly's Combo Therapy Succeeds In Late-Stage Lung Cancer Study
FDA Approves Bavencio Plus Inlyta Combination For Patients With Advanced Renal Cell Carcinoma
Teva Migraine Drug Helps To Contain Q1 2019 Profit Fall
Sanofi Wins U.S. Approval To Sell Dengue Vaccine, But With Major Restrictions
Mylan shares sink as bleak profit outlook for 2019 sparks growth concerns
U.S. Supreme Court Rejects Allergan Bid To Use Tribe To Shield Drug Patents
AstraZeneca-Daiichi Breast Cancer Treatment Shows Promise In Latest Study
Johnson & Johnson To Submit Applications For At Least 10 New Drugs By 2023
Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen
GSK's 3-In-1 Inhalable Drug Shows Promise In Asthma Study
Gilead To Separate Kite Cell Therapy Unit
Lundbeck and Otsuka's antipsychotic drug Rexulti fails two bipolar late-stage studies
AbbVie's Psoriasis Treatment Drug Skyrizi Wins U.S. Approval
Amgen Sets $21,900 Annual Price For New Evenity Bone Drug
Eli Lilly Misses Estimates For Top-Selling Diabetes Drug Trulicity, Shares Slip
Amicus Therapeutics to hire 200 researchers at new gene therapy center in Philadelphia
Alnylam’s RNAi Therapy For Acute Hepatic Porphyria Positive In Phase III
Bayer Shares Near Seven-Year Low After $2+ Billion Award In Roundup Trial
Regeneron’s Eylea Wins FDA Approval For Diabetic Retinopathy
Gilead Sciences To Provide Free Truvada For PrEP To Support U.S. Initiative To End HIV Epidemic
Swiss Drugmaker Roche Ups 2019 Outlook As Q1 Sales Growth Offsets Price Hit
Takeda Pharmaceutical Is Building Up Company’s U.S. R&D Presence
FDA approves Dr. Reddy’s Tosymra
Exclusive: Astellas’ Xospata Provides Strong OS Benefits In Phase III Trial
Out From Under Novartis, Alcon Is Its Own Company Now
Ireland Demands $1.9 Billion In Back Taxes From Perrigo
Alexion’s Ultra-Rare Kidney Disease Drug Passes Phase III With Flying Colors
FTC loses Shire appeal, losing round in fight against citizen petition abuse
Merck Raises Full-Year Forecasts As Vaccines Power Profit Beat
Novartis Gets Approval To Sell Kymriah In Japan For $306,000
Bristol-Myers Shareholders Vote To Approve Celgene Takeover
Novo Nordisk Profit Tops Forecast As New Diabetes Drug Shines
Ad Right Top
Latest News
U.S. FDA issues recall of Ethicon’s surgical staplers
The U.S. Food and Drug Administration issued a recall of surgical staplers made by Johnson & Johnson’s Ethicon unit, warning that the use of the devices could cause serious injury or death.
Agios Pharma’s Tibsovo Shows Positive Results in Phase III for Another Cancer Indication
Cambridge, Mass.-based Agios Pharmaceuticals announced that Tibsovo (ivosidenib) hit the primary endpoint in the Phase III ClarIDHy trial in patients with cholangiocarcinoma with an isocitrate dehydrogenase 1 mutation.
Most Recent
Most Recent
Most Commented
Sorry. No data so far.
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!